Using FDA Databases, 510(k) Clearances, Drug Approval Data, Facility Registration Records, Warning Letters and Clinical Trial Registrations for Healthcare and Life Sciences Prospecting
On this page
FDA Data as a Business Intelligence Source
The FDA maintains dozens of publicly searchable databases covering medical devices, pharmaceuticals, biologics, food facilities, clinical trials and enforcement actions. These databases reveal which companies are developing new products, receiving regulatory clearances, manufacturing in specific facilities, receiving warning letters and conducting clinical trials. For healthcare and life sciences sales teams, this data provides actionable prospecting intelligence:
| FDA database | What it contains | Update frequency | Prospecting value |
|---|---|---|---|
| 510(k) Premarket Notification (accessdata.fda.gov) | Medical device clearance decisions: device name, applicant, product code, decision date, predicate device | Weekly | Identifies companies that just received clearance for a new medical device (they need manufacturing, packaging, sterilisation, distribution, marketing services) |
| PMA (Premarket Approval) database | High-risk medical device approvals (Class III): applicant, device, approval date, supplements | Monthly | Identifies companies launching high-risk devices (longer sales cycle; higher value; need clinical evidence, post-market surveillance, REMS) |
| De Novo Classification database | Novel low-to-moderate risk devices without predicates: applicant, device, decision date | Monthly | First-of-kind devices entering market; company creating a new product category |
| Orange Book (Approved Drug Products) | FDA-approved drugs: NDA/ANDA number, active ingredient, applicant, approval date, patent and exclusivity data | Daily | New drug approvals signal manufacturing, commercialisation, marketing and distribution needs |
| FDA Facility Registration (FEI database) | Registered drug and device manufacturing facilities: firm name, address, FEI number, registration status | Annual (October renewal) | All FDA-registered manufacturing sites; identifies manufacturers by location and product type |
| FDA Warning Letters | Warning letters issued to companies for regulatory violations: company name, date, violation type, product type | Weekly | Companies receiving warning letters need regulatory consultants, quality system remediation, CAPA implementation, laboratory services |
| Import Alerts | Products and firms on import alert (detention without physical examination): firm name, country, product, alert reason | Ongoing | Foreign manufacturers blocked from US import need compliance consultants, testing laboratories, US-based manufacturing alternatives |
| Clinical Trials (ClinicalTrials.gov, not FDA but related) | Clinical trial registrations: sponsor, study title, phase, conditions studied, sites, dates, recruitment status | Daily | Companies running clinical trials need CROs, clinical supplies, site management, data management, regulatory writing |
| Establishment Inspection Reports (EIR) | Results of FDA facility inspections: firm name, inspection date, classification (NAI, VAI, OAI) | Ongoing | Inspection outcomes reveal compliance status; OAI classification may trigger warning letter or consent decree |
| MAUDE (Manufacturer and User Facility Device Experience) | Medical device adverse event reports: device name, manufacturer, event type, event date | Monthly | Adverse event trends may signal recall risk, redesign needs, quality system issues |
Prospecting Applications by Service Type
Medical device services
| Service you sell | FDA data signal | How to use it |
|---|---|---|
| Contract manufacturing (medical device) | 510(k) clearance for a company without in-house manufacturing capability (startups, small companies) | "Congratulations on receiving 510(k) clearance for [device name] on [date]. As you scale from prototype to commercial production, [Company] manufactures [device type] in our FDA-registered, ISO 13485-certified facility..." |
| Sterilisation services | 510(k) clearance for a device requiring sterilisation (surgical instruments, implants, wound care) | "Your [device name] clearance indicates a sterile device. [Company] provides [EO / gamma / e-beam / steam] sterilisation at our FDA-registered facility, with validation protocols and bioburden testing..." |
| Regulatory consulting | FDA Warning Letter to medical device company | "Your Warning Letter dated [date] cited [violation categories]. Responding within the 15-business-day deadline requires: [corrective action plan]; [root cause analysis]; [CAPA implementation]; [quality system remediation]; [documentation and evidence]. [Company] has assisted [X] companies in responding to FDA Warning Letters, with [X]% achieving subsequent satisfactory inspection outcomes..." |
| Quality system software | 510(k) clearance or PMA approval (company needs to maintain quality system documentation) | "With [device name] cleared/approved, your quality management system must support: [design controls]; [CAPA]; [complaint handling]; [document control]; [supplier management]; [audit management]. [Company] provides FDA 21 CFR Part 820 compliant QMS software..." |
| Clinical research (CRO) | Clinical trial registration at ClinicalTrials.gov showing recruiting status | "Your Phase [X] trial for [condition] (NCT[number]) is currently recruiting at [X] sites. [Company] provides [monitoring / data management / biostatistics / regulatory writing / site management] for [therapeutic area] trials..." |
| Packaging and labelling | 510(k) clearance (device needs commercial packaging and labelling before market launch) | "Your 510(k) clearance for [device name] means packaging and labelling development is next. [Company] designs and produces [sterile barrier packaging / device packaging / IFU printing / UDI-compliant labelling]..." |
Pharmaceutical services
| Service you sell | FDA data signal | How to use it |
|---|---|---|
| Contract manufacturing (pharma) | NDA or ANDA approval for a company without commercial-scale manufacturing | "Your [NDA/ANDA] approval for [drug name] on [date] moves you from development to commercial supply. [Company] manufactures [dosage form: tablet / capsule / injectable / topical] at our FDA-registered, cGMP facility..." |
| Analytical testing laboratory | FDA Warning Letter citing laboratory control failures; new drug approval requiring stability testing | "Your Warning Letter cited [laboratory control deficiencies]. [Company] provides [method validation / stability testing / release testing / raw material testing] from our FDA-registered, GMP-compliant laboratory..." |
| Regulatory consulting (pharma) | FDA Complete Response Letter (drug not approved; deficiencies cited) | "Your Complete Response Letter for [drug name] cited [deficiency categories]. [Company] assists sponsors in addressing CRL deficiencies: [CMC remediation / clinical data analysis / labelling revision / REMS development]..." |
| Drug distribution and 3PL | New drug approval (company needs US distribution capability) | "With [drug name] approved, you need distribution: [cold chain if applicable]; [serialisation and track-and-trace]; [DEA compliance (if controlled substance)]; [state licensing]; [wholesale distribution]. [Company] provides FDA-compliant pharmaceutical 3PL services..." |
Data Access Methods
| Database | Access method | Data format | Best for |
|---|---|---|---|
| 510(k) database (accessdata.fda.gov) | Web search; downloadable ZIP files | HTML (search results); CSV (bulk download) | Individual device clearance lookup; bulk analysis of clearances by product code, applicant or date |
| PMA database | Web search; downloadable files | HTML; CSV | Class III device approval monitoring |
| Orange Book | Web search; downloadable files | HTML; CSV | Drug approval monitoring; patent and exclusivity analysis |
| FDA Warning Letters | Web search (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) | HTML | Compliance-driven prospecting |
| Facility Registration (FEI) | Web search; FOIA requests for bulk data | HTML | Manufacturer identification by location and product type |
| ClinicalTrials.gov | Web search; API (ClinicalTrials.gov/api/v2) | HTML (search); JSON (API) | Clinical trial sponsor identification; site identification |
| openFDA API (open.fda.gov) | REST API | JSON | Programmatic access to device clearances, drug events, recalls, enforcement actions |
| FDA CDRH Annual Report | PDF download | Device industry trends and statistics | |
| MAUDE | Web search; downloadable files | HTML; CSV | Adverse event trend analysis by device or manufacturer |
Terms of Service
| Allowed | Not allowed |
|---|---|
| Accessing and downloading FDA public data | Automated scraping at excessive rates (use API or bulk downloads instead) |
| Using FDA data for business intelligence | Misrepresenting FDA data or decisions |
| Building databases from bulk downloads and API data | Implying FDA endorsement of your products or services |
| Monitoring warning letters and enforcement actions | Using data to harass or defame companies or individuals |
| Analysing clinical trial data for competitive intelligence | Accessing non-public FDA data without authorisation |
Processing FDA Data for Prospecting
FDA databases identify companies, products, regulatory decisions and facilities, but contain limited direct contact information (typically just the company name and registered address). To build a prospectable list, combine FDA-derived company intelligence with contact information from company websites (HTML), LinkedIn company pages, industry association directories (AdvaMed, PhRMA, BIO -- HTML), trade show exhibitor lists (MD&M, BIO International, CPhI -- CSV), clinical trial site listings (ClinicalTrials.gov -- HTML) and state professional licence databases (HTML). Upload all source files to Email Extractor to extract and deduplicate email addresses across sources. A medical device company that just received 510(k) clearance has contacts on its website, at industry conferences, in association directories and across regulatory filing contacts, so deduplication creates a clean prospect list enriched with FDA-derived intelligence about their regulatory status, product pipeline and compliance history.
